AbbVie (ABBV) Q4 FY24 earnings call

AbbVie concluded 2024 with strong Q4 performance, driven by its ex-Humira platform, which delivered over 18% full-year sales growth and accelerated to 22% in Q4. This robust performance, particularly from Skyrizi and Rinvoq, positions the company for mid-single-digit revenue growth in 2025 and beyond, despite significant Humira erosion and Medicare Part D headwinds. The company also advanced its pipeline with key regulatory approvals and promising data, while strategically pursuing external innovation to fuel future growth.